J

Johnson & Johnson

Makes prescription drugs and medical devices

Vision Care Associate Manager - Owned Web & Digital Implementation

Full-Time
No salary listed
Mid, Senior
Chiyoda City, Tokyo, Japan
Hybrid
Growth & MarketingGrowth Marketing

About the job

Requirements
  • Three to seven years of hands-on experience in web production, CMS implementation, and front-end delivery in B2C or equivalent consumer-facing environments.
  • A proven track record delivering measurable conversion-rate and user-experience improvements on corporate or brand websites through A/B testing and iterative releases.
  • Practical experience implementing technical search engine optimization and CMS component work within a global CMS framework or governed template system.
  • Direct experience implementing tag management and analytics, including UTM strategy, event/dataLayer design, and Google Tag Manager or similar, while ensuring data quality for reporting.
  • Experience implementing web features that drive offline store visits and measuring web-to-store outcomes.
  • Experience integrating website events with CRM, CDP, or marketing automation systems, including data capture, consent flows, and event forwarding.
  • Working knowledge of privacy and data-protection needs for website data collection, including GDPR/CCPA-aware implementation practices.
  • Ability to create implementation-ready prototypes using Figma, Adobe XD, or equivalent.
  • Experience with web analytics and experimentation tools such as GA4 or equivalent and A/B testing tools, and basic SQL for ad-hoc analysis.
  • Familiarity with tag management and tracking, including dataLayer design and pixel/tag troubleshooting.
  • Familiarity with CMS template/component configuration, release workflows, and staging/production deployments.
  • Basic understanding of front-end implications, including HTML/CSS/JS basics and their effects on SEO and performance.
  • Comfort with issue-tracking and release-coordination tools such as Jira, Confluence, or similar.
  • Ability to formulate hypotheses, define key performance indicators, run tests, interpret results, and prioritize fixes.
  • Ability to manage multiple technical tasks, perform quality assurance, and deliver releases under deadlines.
Responsibilities
  • Operate and maintain the corporate and brand websites in day-to-day production, including content publishing, CMS component configuration, release management, and quality assurance within global CMS governance and compliance requirements.
  • Implement CMS changes and front-end components based on intake requirements, and produce implementation-ready design artifacts and developer hand-offs, including Figma and Adobe XD prototypes.
  • Implement technical SEO tasks affecting organic presence, including SEO tagging, metadata, structured data, sitemap updates, canonicalization, and performance improvements in collaboration with IT and external partners.
  • Design and implement UX improvements and conversion funnels by analyzing web access and behavioral data, mapping user journeys, defining target journeys by audience cohort, and implementing page- and flow-level optimizations to improve conversion rate.
  • Prototype MVP pages and content, deploy A/B and multivariate experiments, measure results, and iterate based on data; manage the experiment lifecycle from hypothesis and tagging through quality assurance and result analysis.
  • Implement and govern tracking, including UTM strategy, analytics tags, dataLayer/event taxonomy, Google Tag Manager or equivalent configuration, and tag testing to ensure accurate measurement and attribution.
  • Design and execute web-to-store initiatives, including store-locator user experience, reservation and appointment flows, click-to-call, unique campaign codes, and QR-driven experiences; measure offline attribution where possible.
  • Manage integrations between the website and CRM/marketing automation, ensuring registration, event, and consent data flows are implemented correctly and supporting first-party data capture for lifecycle marketing.
  • Act as the local implementer for global digital solutions by translating global components for local user-experience and technical constraints, performing local implementation, validating vendor deliverables, and providing feedback to global teams.
  • Ensure implementations comply with applicable privacy and regulatory requirements, and support opt-in flows and consent management in collaboration with legal and business intelligence teams.
  • Produce operational documentation, including release notes, runbooks, and tagging maps, and maintain a prioritized backlog of website improvements.
  • Work with IT/Technology to implement technical changes and enforce release governance.
  • Partner with Brand Marketing to translate marketing goals into web requirements and key performance indicator definitions.
  • Coordinate with business intelligence and data teams to validate data flows and ensure measurement fidelity.
  • Engage external agencies and vendors as implementers and quality-assurance partners, and act as the local point of contact for global vendor deliverables.
  • Proactively obtain necessary inputs, escalate blockers early, and drive execution.
Desired Qualifications
  • Hands-on experience with global CMS deployments and adapting global components for local markets.
  • Prior work in regulated industries, such as healthcare, pharma, or finance, where privacy and compliance affect web implementation.
  • Familiarity with web-to-store attribution methods and offline measurement techniques.
  • Experience working with LINE or other local messaging platforms for registration/CRM flows.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.